Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ventrus Completes Clinical Development Staffing
NEW YORK , Feb. 1, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the completion of its clinical development staffing. Ventrus has contracted Mohan Kabadi , Ph.D.
View HTML
Toggle Summary Underwriters Exercise Over-Allotment Option for Ventrus Biosciences' Initial Public Offering
Underwriters Exercise Over-Allotment Option for Ventrus Biosciences' Initial Public Offering NEW YORK, Jan. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced
View HTML
Toggle Summary Ventrus Biosciences Announces Closing of Initial Public Offering of Common Stock
Ventrus Biosciences Announces Closing of Initial Public Offering of Common Stock NEW YORK, Dec. 23, 2010 (GLOBE NEWSWIRE) -- Ventrus Biosciences Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it
View HTML
Toggle Summary Ventrus Biosciences Announces Pricing of Its Initial Public Offering
Ventrus Biosciences Announces Pricing of Its Initial Public Offering NEW YORK, Dec. 16, 2010 (GLOBE NEWSWIRE) -- Ventrus Biosciences Inc. ("Ventrus") (Nasdaq: VTUS ), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its
View HTML